SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration showing line of people leaving, standing on top of hand pointing their way out
Layoffs
Leap Slashes 75% of Workforce, Explores Strategic Options
In addition to cutting most of its staff, including two C-suite executives, Leap Therapeutics is winding down research and development activities and considering a sale or partnership opportunities.
June 24, 2025
 · 
1 min read
 · 
Angela Gabriel
Illustration showing scientist climbing up DNA spiral staircase
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C. Wainwright. Sangamo plans to use pivotal Phase I/II data to build an accelerated approval case for the asset.
June 24, 2025
 · 
3 min read
 · 
Tristan Manalac
Passenger plane takes off from runway. Air transport, vector illustration
Deals
Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal
In May, Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.
June 24, 2025
 · 
1 min read
 · 
Annalee Armstrong
People And Robots Handshake Modern Human And Artificial Intelligence Futuristic Mechanism Technology Vector Illustration
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.
June 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk and Eli Lilly buildings
Weight loss
Lilly’s Antibody Protects Patients From Losing Muscle While Taking Novo’s Wegovy
Eli Lilly’s bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, marketed by rival Novo Nordisk as Wegovy. BMO Capital Markets called the data “impressive” while raising concerns about the antibody’s safety profile.
June 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Opinion
Washington’s Policy Shifts Are Driving Capital Away From Life-Saving Research
Drug pricing, budget cuts, tariffs and other shifts under the Trump administration undermine the biopharma and healthcare ecosystem.
June 24, 2025
 · 
4 min read
 · 
John Stanford
Pictured: (From L) Joe Ross, Camille Bedrosian, Emil Kakkis and Heather McKenzie
Rare diseases
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway proposed by FDA Commissioner Marty Makary. They acknowledged, however, that creative thinking is required to enable more treatments for patients with ultrarare diseases.
June 24, 2025
 · 
3 min read
 · 
Heather McKenzie
A group of people sitting before microphones at a table on a stage
Government
Acting CDER Head Becomes Latest in String of FDA Leaders to Leave Agency
Jacqueline Corrigan-Curay, who stepped into the role as the agency’s top drug regulator in January, is departing in July, according to an email sent to agency staff.
June 23, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Isometric Breaking the Wall. An alternative Solution to the Problem. Businessman Solved Problem, New Solution, Success and Leadership. Breakthrough. Business concept.
Weight Loss
Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack
While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, analysts from William Blair worried that adverse events are not tapering off as expected.
June 23, 2025
 · 
5 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS